| Prev Close | 3.37 |
| Day Low/High | 3.28 / 3.41 |
| 52 Wk Low/High | 1.65 / 4.69 |
| Exchange | NASDAQ |
| Shares Outstanding | 20.07B |
| Market Cap | 67.62M |
| Div & Yield | N.A. (N.A) |
Latest News
Imprimis Pharmaceuticals And SightLife Surgical Sign Agreement For National Launch Of Serum Tears™
Imprimis begins roll-out of dry eye disease formulary with innovative autologous serum eye drop program
Imprimis Pharmaceuticals And Precision Lens Sign Agreement To Expand Imprimis' Ophthalmic Portfolio Market Opportunity In The U.S. Midwest
Largest distributor of ophthalmic products in the Midwest to expand Imprimis' ability to serve strategic accounts and accelerate growth
Imprimis Pharmaceuticals Acquires Exclusive License To Patented Ophthalmic Formulation For Dry Eye Disease
Formulation Expected to be a Cornerstone of Imprimis' New Dry Eye Program
Peer-Reviewed Paper Demonstrates The Benefits Of Dropless Cataract Surgery®
Compliance, cost-savings and efficacy listed as key reasons to adopt Dropless Therapy®
Imprimis Pharmaceuticals Begins Dispensing From FDA-Registered 503B Outsourcing Facility
Improved efficiencies and additional revenue opportunities expected for Imprimis' ophthalmic portfolio
Imprimis Pharmaceuticals And FocusScript Partner To Exclusively Offer The Correct Compound™ Program
The Correct Compound™ program combines the cost savings of the Imprimis Cares® portfolio of compounded medications with FocusScript's accredited and credentialed network, proprietary Compound Drug Formulation Logic program (CDF-Logic™) and world-class suite of prescription drug processing tools
Imprimis Pharmaceuticals Ranked 12 On Deloitte's 2016 Technology Fast 500™ List Of Fastest Growing Companies In North America
Imprimis attributes significant growth to innovative business model and growing demand for its Imprimis Cares® portfolio of cost-effective compounded medications
Imprimis Pharmaceuticals Signs Agreement With Specialty Pharmacy Division Of One Of The Nation's Largest Pharmacy Benefit Managers
Agreement to supply Imprimis Cares complete formulary streamlines the drug dispensing model, creating a new solution to lower drug costs for patients, physicians, health insurance plans and employers
Imprimis Pharmaceuticals To Host Its Third Quarter 2016 Financial Report
Conference Call and Webcast on November 14, 2016 at 4:30 p.m. EST
Imprimis Pharmaceuticals Registers Its New Jersey Facility With The FDA As An Outsourcing Facility
Improved efficiencies and additional revenue opportunities expected for Imprimis' Proprietary Dropless Therapy® Injectable and LessDrops® Topical Formulations
Imprimis' Dropless Therapy Shows Significant Advantages In A Large Peer-Reviewed Study
Compounded prophylactic formulation provides benefit for cataract patients following surgery
Imprimis Pharmaceuticals Announces Availability Of Lower-Cost Option For The Treatment Of Lead Poisoning
Imprimis' $495 EDTA calcium disodium injectable formulation provides significant cost savings compared to Valeant's $27,000 drug
Imprimis Pharmaceuticals' Formulations To Be Highlighted At Upcoming Annual Ophthalmology Meeting In Chicago
Planned events and sessions will highlight Dropless Therapy®, LessDrops® combination drop therapy and IV-Free MKO Melt conscious sedation formulations
Imprimis Pharmaceuticals' CEO Mark L. Baum To Debate At The Oxford Union Debating Society
Baum to argue in favor of the debate motion: "Big Pharma Prioritizes Profits Over Patients"
Imprimis Pharmaceuticals Accelerates Profitability Timeline By Implementing Expense Reduction Program
Cost reduction strategies to improve efficiencies and position company for sustainable growth
Following Congressional Hearing Investigating Mylan And Epi-Pen, Imprimis Pharmaceuticals Founder And CEO Publishes Drug Pricing Monograph
Safe pharmaceutical compounding can play an invaluable role in resolving the U.S. drug pricing crisis
Imprimis Pharmaceuticals Launches Imprimis Cares Access Network (ICAN) to Assist in Patient Access to Imprimis Cares® Compounded Formulations
ICAN program designed to facilitate the insurance payment process and substantially reduce or eliminate patient payment challenges
EpiPen Price Relief Could Come From Rivals Before Politicians
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
Imprimis Pharmaceuticals Strengthens Senior Leadership Team With Key Hires In Operations, Quality, Manufacturing And Client Relations
Four industry leaders bring significant depth of experience to drive Imprimis' next phase of growth
Imprimis Launches New MaxRx Prescriber Portal™
MaxRx™ software is a key tool to optimize customer experience; Imprimis continues to integrate new processes and systems to scale its business
Peer-Reviewed Study Of Dropless Cataract Surgery Shows 'Measurable Benefits' Compared To Drops
Journal of Clinical Ophthalmology reports 'strong patient preference' for Imprimis Pharmaceuticals' Dropless Therapy® formulation
